Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment

Copyright © 2021 Elsevier B.V. All rights reserved..

Alloantibodies, in particular immunoglobulin G (allo-IgG), confer a rejection advantage to tumors sharing the same major histocompatibility complex (MHC) in mice. However, when administrated intratumorally, this effect can only be achieved in combination with dendritic cells (DCs) activation. Here, we developed high titer allo-IgG by multiple rounds of immunization with allogenic B16 melanoma cells, which allows for the strong binding with B16 cells. We demonstrate that B16 cells incubated with these allo-IgG (referred to as allo-IgG-B16) become highly immunogenic, which release tumor antigens that are efficiently presented by classic DCs in lymph nodes (LNs). Injection of allo-IgG-B16 turns the tumor into an immune hot one and even elicits a systemic antitumor response when used together with 5-fluorouracil (5-FU). This systemic response is tumor-specific and relies on the critical site - LNs. Our findings provide a rationale for the use of allo-IgG in cancer treatment.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:503

Enthalten in:

Cancer letters - 503(2021) vom: 10. Apr., Seite 151-162

Sprache:

Englisch

Beteiligte Personen:

Dang, Nana [VerfasserIn]
Lin, Yuan [VerfasserIn]
Waer, Mark [VerfasserIn]
Sprangers, Ben [VerfasserIn]

Links:

Volltext

Themen:

CD8(+) T cells
Dendritic cells
Fluorouracil
Immunoglobulin G
Isoantibodies
Journal Article
Lymph nodes
Regulatory T cells
Research Support, Non-U.S. Gov't
Tumor antigens
U3P01618RT

Anmerkungen:

Date Completed 05.08.2021

Date Revised 05.08.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.canlet.2021.01.027

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM321057961